Loading company
Anbio Biotechnology
NNNN · Nasdaq · ·
$6.16+2.2%Sep 29 close
- 1M
- -19.7%
- 6M
- -75.0%
- 1Y
- -83.5%
Anbio Biotechnology is the 34th largest of 48 graded companies. Showing 5 of them, including NNNN itself. 2 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Intuitive Surgical, Inc.ISRG | A+ | $145.6B | $11B | 28.4% | $3.2B | 47.27 |
| Becton, Dickinson And CompanyBDX | B | $49.6B | $23.3B | 4.0% | $2.6B | 54.82 |
| ResMed Inc.RMD | B+ | $32.2B | $5.7B | 26.9% | $1.6B | 21.37 |
| Alcon Inc.ALC | B | $31.9B | $9.5B | 10.3% | $1.7B | 33.05 |
| Anbio BiotechnologyNNNN | B+ | $269M | $8.6M | 74.1% | — | 41.90 |
43 more medical instruments and supplies companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Anbio Biotechnology on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
NNNN · Nasdaq · ·
$6.16+2.2%Sep 29 close